NCT00325429已完成3 期
A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Adverse events profile after 52 weeks of treatment
研究概览
简要总结
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in patients with type 2 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of type 2 diabetes
- •Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels
- •Outpatients
排除标准
- •Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- •Significant cardiovascular complications as defined by the protocol
- •Significant diabetic complications as defined by the protocol
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Adverse events profile after 52 weeks of treatment
次要结局
- Change from baseline to endpoint on HbA1c at 52 weeks
- Change from baseline to endpoint in body weight at 52 weeks
- Change from baseline to endpoint on fasting plasma glucose at 52 weeks
- Change from baseline to endpoint in HOMA IR at 52 weeks
- Change from baseline to endpoint in HOMA B at 52 weeks
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea MonotherapyDiabetes Mellitus, Type 2NCT00325117Novartis200
已完成
3 期
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00351832Novartis236
已完成
3 期
Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild HyperglycemiaDiabetes Mellitus, Type 2NCT00101712Novartis Pharmaceuticals274
已完成
3 期
Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%Diabetes Mellitus, Type 2NCT00101673Novartis Pharmaceuticals251
已完成
3 期
Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00102388Novartis Pharmaceuticals1,092